Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study Of Bupropion SR (323U66) In Patients With Major Depressive Disorder In Japan

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00330616
Recruitment Status : Completed
First Posted : May 29, 2006
Results First Posted : March 20, 2009
Last Update Posted : May 4, 2015
Sponsor:
Information provided by:
GlaxoSmithKline

Brief Summary:
This is a study to obtain clinical experience of 323U66 SR for elderly patients with depression in repeat-dose of 323U66 SR up to 300mg/day, and to conduct exploratory investigation on safety, efficacy and pharmacokinetics profile in elderly patients with depression.

Condition or disease Intervention/treatment Phase
Major Depressive Disorder (MDD) Drug: 323U66 SR Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 35 participants
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Evaluation of Bupropion SR (323U66)in Patients With Depression - Investigation in Elderly Patients With Depression
Study Start Date : May 2006
Actual Primary Completion Date : November 2007
Actual Study Completion Date : November 2007

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Change From Baseline in Hamilton Rating Scale for Depression (HAM-D) Total Score at Week 8 [ Time Frame: Baseline and Week 8 ]
    The Hamilton Rating Scale for Depression (HAM D) contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAM D score range from 0 (not ill) to 53 (severely ill).


Secondary Outcome Measures :
  1. Percentage Change From Baseline in Hamilton Rating Scale for Depression (HAM-D) Total Score at Week 4 [ Time Frame: Baseline and Week 4 ]
    The Hamilton Rating Scale for Depression (HAM D)contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAM D score range from 0 (not ill) to 53 (severely ill).

  2. Percentage Change From Baseline in Hamilton Rating Scale for Depression (HAM-D)Total Score at Week 8 [ Time Frame: Baseline and Week 8 ]
    The Hamilton Rating Scale for Depression (HAM D)contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAM D score range from 0 (not ill) to 53 (severely ill).

  3. Percentage of Responders Based on the Hamilton Rating Scale for Depression (HAM-D) at Week 4 [ Time Frame: Week 4 ]
    The Hamilton Rating Scale for Depression (HAM D)contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAM D score range from 0 (not ill) to 53 (severely ill). Responders are defined as subjects that had a decrease of >/= 50% total score on the HAM D.

  4. Percentage of Responders Based on the Hamilton Rating Scale for Depression (HAM-D) at Week 8 [ Time Frame: Week 8 ]
    The Hamilton Rating Scale for Depression (HAM D)contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAM D score range from 0 (not ill) to 53 (severely ill). Responders are defined as subjects that had a decrease of >/= 50% total score on the HAM D.

  5. Percentage of Remitters Based on the Hamilton Rating Scale for Depression (HAM-D) at Week 4 [ Time Frame: Week 4 ]
    The Hamilton Rating Scale for Depression (HAM D)contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAM D score range from 0 (not ill) to 53 (severely ill). Remitters are defined as subjects with a HAM D total score of </= 7.

  6. Percentage of Remitters Based on the Hamilton Rating Scale for Depression (HAM-D) at Week 8 [ Time Frame: Week 8 ]
    The Hamilton Rating Scale for Depression (HAM D)contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAM D score range from 0 (not ill) to 53 (severely ill). Remitters are defined as subjects with a HAM D total score of </= 7.

  7. Change From Baseline in Hamilton Rating Scale for Depression (HAM-D) of Each Question's Score at Week 4 [ Time Frame: Baseline and Week 4 ]
    The Hamilton Rating Scale for Depression (HAM D)contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAM D score range from 0 (not ill) to 53 (severely ill).

  8. Change From Baseline in Hamilton Rating Scale for Depression (HAM-D) for Each Question's Score at Week 8 [ Time Frame: Baseline and Week 8 ]
    The Hamilton Rating Scale for Depression (HAM D)contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAM D score range from 0 (not ill) to 53 (severely ill).

  9. Percentage of Change From Baseline in Hamilton Rating Scale for Depression (HAM-D)for Each Question's Score at Week 4 [ Time Frame: Baseline and Week 4 ]
    The Hamilton Rating Scale for Depression (HAM-D)contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAM-D score range from 0 (not ill) to 53 (severely ill).

  10. Percentage of Change From Baseline in Hamilton Rating Scale for Depression (HAM-D) for Each Question's Score at Week 8 [ Time Frame: Baseline and Week 8 ]
    The Hamilton Rating Scale for Depression (HAM-D)contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAM D score range from 0 (not ill) to 53 (severely ill).

  11. Hamilton Rating Scale for Depression (HAM-D) Total Score at Week 4 and Week 8 [ Time Frame: Week 4 and Week 8 ]
    The Hamilton Rating Scale for Depression (HAM-D)contains 17 questions which detect change and measure illness severity. Individual items are rated on a scale of 0-4, 0-3, and 0-2 with total HAM D score range from 0 (not ill) to 53 (severely ill).

  12. Percentage of Responders Based on the Clinical Global Impression - Global Improvement Score (CGI-I)at Week 4 and Week 8 [ Time Frame: Week 4 and Week 8 ]
    The CGI-I assesses the investigator's impression of the patient's current illness. The time span is the week before the rating and the score ranges from 1 (very much improved) to 7 (very much worse). Responders are subjects that have a score of 1 (very much improved) or 2 (much improved) on the CGI-I.

  13. Change From Baseline in Clinical Global Impression (CGI) Severity of Illness Score at Weeks 1, 2, 3, 4, 8 [ Time Frame: Baseline, Weeks 1, 2, 3, 4, 8 ]
    The CGI-S assesses the investigator's impression of the severity of the patient's current illness. The time span is the week before the rating and the score ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients).

  14. Adverse Events (>=5% Incidence) [ Time Frame: Baseline through Week 8 ]
  15. Serious Adverse Events [ Time Frame: Baseline through Week 8 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   65 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Target disease: Patients diagnosed as having the following primary disease and current major depressive episode for at least 8 weeks on the basis of DSM-IV-TR criteria.

    • Major Depressive Disorder, Single Episode (296.2x) (excluding those with psychotic features)
    • Major Depressive Disorder, Recurrent (296.3x). (excluding those with psychotic features)
  • HAM-D (17 items) total score >/=18.
  • Age: >/=65 years old (at the time of informed consent)
  • Gender: Male or female.
  • Inpatient or outpatient status: Either
  • Informed consent: The subject himself/herself must give written informed consent.

Exclusion criteria:

  • Patients with predisposition to seizure (who currently have or have a past history of seizure, febrile convulsive seizure in infancy, cerebral tumour, cerebrovascular disorder or head injury, who have a family history of idiopathic seizure, patients with diabetes who have been treated with oral hypoglycaemics or insulin, or who use drugs lowering the threshold of seizure)
  • Patients who currently have or have a past history of the following disorders:

    • Anorexia nervosa (DSM-IV-TR 307.1)
    • Bulimia nervosa (DSM-IV-TR 307.51)
  • Patients with a history of manic episode
  • Patients with a past or current DSM- IV-TR diagnosis of schizophrenia or other psychotic disorder
  • Patients with a current DSM-IV-TR Axis II diagnosis (e.g., antisocial or borderline personality disorder)
  • Patients starting psychotherapy (except for supportive psychotherapy not aimed at therapeutic efficacy and unlikely to affect efficacy evaluation) and standardized cognitive behaviour therapy within 12 weeks prior to the start of the treatment phase
  • Patients with a diagnosis of substance abuse (alcohol or drug) by the DSM-IV-TR criteria or with a diagnosis of substance dependence within 1 year prior to the start of the treatment phase
  • Patients who have received electroconvulsive therapy within 24 weeks prior to the start of the treatment phase
  • Patients who have taken MAO inhibitors (selegiline hydrochloride) within 2 weeks prior to the start of the treatment phase
  • Patients who have taken another investigational drug within 12 weeks prior to the start of the pre-treatment phase
  • Patients who have attempted suicide within 24 weeks prior to the start of the treatment phase, or patients for whom the score of the suicide-related item of HAM-D is >/=3, or patients in whom the risk of suicide is judged to be high by the investigator (sub-investigator).
  • Patients in whom the risk of homicide is judged to be high by the investigator (sub-investigator).
  • Patients with a history of hypersensitivity to 323U66
  • Patients with serious cerebral disease
  • Patients who have ECG or clinical evidence of any cardiac condition that the investigator (sub-investigator) assesses the subject is predisposed to ischemia or arrhythmia
  • Patients with serious physical symptoms (i.e. cardiac/hepatic/renal disorder, hematopoietic disorder).

The index of seriousness is Grade 3 of "Criteria for classification of seriousness of adverse drug reactions to pharmaceutical products, etc." (PAB/PSD No.80 in 1992).

  • Patients who have a history or complicated carcinoma or malignant tumour.
  • Patients whose major depressive disorder is due to direct physiological effects of a general medical condition (for example, hypothyroidism, Parkinson's disease, chronic pain)
  • Patients with systolic blood pressure of >/=160 mmHg or diastolic blood pressure of >/=100 mmHg at the start of the Treatment Period
  • Patients diagnosed with dementia
  • Patients who are inappropriate for participating in the study in the judgement of the investigator (sub-investigator).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00330616


Locations
Layout table for location information
Japan
GSK Investigational Site
Fukuoka, Japan, 815-0041
GSK Investigational Site
Fukushima, Japan, 961-0021
GSK Investigational Site
Kumamoto, Japan, 861-8002
GSK Investigational Site
Nagano, Japan, 395-0056
GSK Investigational Site
Nagano, Japan, 399-8695
GSK Investigational Site
Saitama, Japan, 332-0012
GSK Investigational Site
Tokyo, Japan, 164-0012
GSK Investigational Site
Tokyo, Japan, 170-0002
GSK Investigational Site
Tokyo, Japan, 189-0012
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Layout table for investigator information
Study Director: GSK Clinical Trials, MD GlaxoSmithKline

Layout table for additonal information
Responsible Party: Study Director, GSK
ClinicalTrials.gov Identifier: NCT00330616     History of Changes
Other Study ID Numbers: AK1102369
First Posted: May 29, 2006    Key Record Dates
Results First Posted: March 20, 2009
Last Update Posted: May 4, 2015
Last Verified: June 2009
Keywords provided by GlaxoSmithKline:
WELLBUTRIN
elderly
depression
Pharmacokinetics
Additional relevant MeSH terms:
Layout table for MeSH terms
Depression
Depressive Disorder
Depressive Disorder, Major
Mood Disorders
Mental Disorders
Behavioral Symptoms
Bupropion
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Dopamine Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Cytochrome P-450 CYP2D6 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Enzyme Inhibitors